Multi-Component Injectable Pain Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management treatments often fail to effectively address severe and chronic pain, leading to significant limitations in patients' quality of life and requiring long-term, non-systematic trials of multiple medications with limited improvement.
Innovation Solution
A pharmaceutical composition comprising a pharmaceutically acceptable solvent, diclofenac or lornoxicam, metamizole or tramadol, and a benzodiazepine, administered injectably or infusably, which combines pain- and inflammation-alleviating effects with muscle relaxation to target multiple pain causes simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pain killers are used to treat severe and chronic pain, then pain relief is attempted, but treatment effectiveness is insufficient and patients experience limited improvement
Solution Approach 1:
The patent combines multiple analgesic agents (NSAIDs like diclofenac or lornoxicam, opioids like tramadol, and adjuvants like metamizole) into a single pharmaceutical composition. This combination approach allows synergistic interaction between different drug classes, thereby improving pain treatment effectiveness and achieving better pain relief outcomes compared to single-agent therapy.
Solution Approach 2:
The pharmaceutical composition is designed to address multiple pain mechanisms simultaneously through its multi-component formulation. The combination of NSAIDs, opioids, and adjuvants provides broad-spectrum pain management that can effectively treat various types of pain (inflammatory, neuropathic, nociceptive) making the treatment universally applicable to different pain profiles.
2Adaptability or versatility
If multiple different pain-alleviating drugs are examined in long-term treatment programs, then treatment options are explored, but the process is non-systematic and results in minimal improvement
Solution Approach 1:
The patent establishes a systematic, pre-planned treatment protocol that combines multiple analgesic agents in a fixed formulation. This preliminary design of the treatment strategy eliminates the need for lengthy, non-systematic trial-and-error processes, as the optimal combination is predetermined based on pharmacological principles and clinical evidence.
Solution Approach 2:
The invention optimizes the dosage parameters and combination ratios of different analgesic agents in the pharmaceutical composition. By carefully adjusting these parameters, the formulation achieves maximum pain relief effectiveness while minimizing the treatment duration required, thus reducing time loss compared to conventional trial approaches.
3Ease of operation
If a single pain-alleviating drug is used, then treatment simplicity is maintained, but it cannot effectively treat individual disease profiles with severe and chronic pain
Solution Approach 1:
The patent merges multiple analgesic agents with different mechanisms of action into a single pharmaceutical composition that maintains ease of administration. This combination formulation simplifies the treatment approach while significantly improving pain treatment effectiveness, as the synergistic interaction of multiple drugs provides comprehensive pain management that single agents cannot achieve.
Data Source
AI summary
The present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is an injectable or infusable pharmaceutical composition, the pharmaceutical composition comprising:a) a pharmaceutically acceptable solvent,b) a first compound comprising diclofenac or a pharmaceutically acceptable salt or solvate thereof,c) a second compound comprising metamizole or tramadol or a pharmaceutically acceptable salt or solvate thereof, andd) a third compound selected as at least one benzodiazepine or a pharmaceutically acceptable salt or solvate thereof,the pharmaceutical composition further comprising a cortisone derivative or a pharmaceutically acceptable salt or solvate thereof.